Pentoxifylline - >98.0%, high purity , Adenosine A2 receptor antagonist, CAS No.6493-05-6, Adenosine A2 receptor antagonist

Item Number

P160702

• Synonyms: 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- | 2a3c | 3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione | Spectrum2_001181 | 1-(5-Oxohexyl)theobromine | DTXSID7023437 | MLS000758298 | SCHEMBL34039 | 3,7-Dimethyl-1-(5-oxohexyl)-3,7-di
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Phosphodiesterase inhibitor. Inhibits synthesis of TNF-α. Broad-spectrum inhibitor of cytokines. Displays anti-inflammatory and antinociceptive properties.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: ANTAGONIST
• Mechanism of action: Adenosine A2 receptor antagonist
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor. Target: PDE Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability, reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation. Pentoxifylline is also an antagonist at adenosine 2 receptors . Pentoxifylline is generally well tolerated. Based on the totality of the available evidence, it is possible that pentoxifylline could have a place in the treatment of IC as a means of improving walking distance and as a complimentary treatment assuming all other essential measures such as lifestyle change, exercise and treatment for secondary prevention have been taken into account . Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled studies are needed to address this issue .